Navigation Links
Second pathway behind HIV-associated immune system dysfunction identified
Date:9/30/2007

Researchers at the Partners AIDS Research Center at Massachusetts General Hospital (PARC-MGH) may have discovered a second molecular switch responsible for turning off the immune systems response against HIV. Last year members of the same team identified a molecule called PD-1 that suppresses the activity of HIV-specific CD8 T cells that should destroy virus-infected cells. Now the researchers describe how a regulatory protein called CTLA-4 inhibits the action of HIV-specific CD4 T cells that control the overall response against the virus. The report will appear in the journal Nature Immunology and is receiving early online release.

Weve shown that a known regulator of the immune system, CTLA-4, is present in elevated levels on the virus-specific CD4 cells that should be managing the bodys response against HIV, says Daniel Kaufmann, MD, of PARC and the MGH Infectious Disease Unit, a co-first author of the paper. We also found that CTLA-4 expression rises as HIV infection progresses and that the molecule switches off CD4 cell function in a way that appears to be reversible.

Expression of the CTLA-4 protein is known to be elevated on activated T cells, those that have encountered a pathogen and are multiplying rapidly to mount an immune response. Studies in cancer patients have shown that the molecule serves to dampen the immune response, and some preliminary investigations in animals and humans have suggested a potential role in HIV infection. The current study was designed to examine how CTLA-4 may be involved in the dysfunction of HIV-specific T cells that leads to the immune-system breakdown of AIDS.

The researchers first found that CTLA-4 was overexpressed on the HIV-specific CD4 T cells of infected individuals who had not yet received antiviral treatment. Levels were highest in those with symptoms of acute infection and second highest in chronically infected participants. CTLA-4 expression was lowest among a group of participants whose immune systems were naturally able to suppress HIV replication without antiviral medications elite controllers in whom viral levels are too low to be detected.

Elevated CTLA-4 expression also correlated with signs of disease progression increased viral load and reduced overall CD4 count. While antiviral treatment caused viral loads to drop significantly after treatment began, it resulted in only modest and slow drops in CTLA-4 expression. In vitro tests of the effects of blocking the CTLA-4 molecule improved the function of HIV-specific CD4 cells. Comparing the effects of blocking CTLA-4 with those of blocking PD-1 or both molecules produced functional improvements that varied considerably between participants, signifying a complex relationship between the pathways controlled by the two molecules.

Both of these pathways contribute to dysfunction of HIV-specific T cells and both may be considered targets for therapeutic intervention. But since their mechanisms are so complicated, further study is needed before clinical trials can be planned, says Kaufmann, an instructor in Medicine at Harvard Medical School (HMS).

Understanding why the immune system fails to control HIV is essential for development of vaccines and new therapies said Bruce Walker, MD, director of PARC-MGH and senior author of the study. These studies suggest that the immune system is turning itself off prematurely in HIV-infected persons, and the big challenge now is to figure out if we can turn it back on, getting it to do what it is supposed to do, without causing collateral damage in the process. Walker is a professor of Medicine at HMS and a Howard Hughes Medical Institute (HHMI) investigator.


'/>"/>

Contact: Sue McGreevey
smcgreevey@partners.org
617-724-2764
Massachusetts General Hospital
Source:Eurekalert

Related medicine news :

1. Surgeons implant second artificial heart
2. Second hope for men with erectile dysfunction
3. Second SARS suspect fuels worry in India
4. Animals Can give us a second chance at life
5. Animals can give us a second chance at life
6. The Harmful Effects Of Secondhand Smoke
7. Second Hand Exposure To Smoke In Childhood Can Cause Respiratory Problems Later
8. HIV Virus Emerging Drug Resistant In UK, Prompting Fear Of A Second Epidemic
9. Women With Breast Cancer At Risk For Developing Second Cancer
10. Stroke Destroys Nearly 32, 000 Neurons In Just A Second!
11. Websites Are Judged In Less Than A Second
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2017)... ... July 25, 2017 , ... Dr. Donna Bergman, professor of ... and published an article in the medical science journal Physical Medicine and Rehabilitation ... article and the research that helped produce it, were written and conducted in ...
(Date:7/25/2017)... (PRWEB) , ... July 25, 2017 , ... ... Winner for its Product Innovation in the prestigious CEO World Awards®. The coveted ... performance, new products and services, CEO case studies, corporate social responsibility, and milestones ...
(Date:7/24/2017)... , ... July 24, 2017 , ... Cheerag D. ... Saint Luke’s Marion Bloch Neuroscience Institute (SLMBNI), part of Saint Luke’s Health ... 2016. , Cheerag D. Upadhyaya, MD. M.Sc., FAANS joins Stanley P. Fisher, ...
(Date:7/24/2017)... ... July 24, 2017 , ... Horizon Goodwill Industries, ... opportunity that helps high school girls succeed in STEM programs as well as ... Goodwill will host over 20 high school girls at their corporate headquarters on ...
(Date:7/24/2017)... , ... July 24, 2017 , ... Every year, thousands ... and educational conference, InstructureCon. Each annual event is coupled with a dynamic theme like ... a James Bond theme, Mission: InstructureCon 0017. , To extend their partnership with ...
Breaking Medicine News(10 mins):
(Date:7/6/2017)... , July 6, 2017 ThriveRx, the nutrition division of ... their families to thrive on nutrition support. To celebrate its ... new site has a fresh new look with improved organization to create ... ... ...
(Date:7/5/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... pharmaceutical company focused on the development of oral drug delivery ... Israel Securities Authority to dual-list its common stock on the ... trading on the TASE on July 12, 2017 under the ... Company, it is expected that Oramed will be included in ...
(Date:7/5/2017)... 2017   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade cell and tissue hypothermic ... today announced that it has reached an agreement with ... shareholder, to modify its existing credit facility effective June ... WAVI agreed to exchange its existing $4.25 million credit ...
Breaking Medicine Technology: